Advertisement

Erroneous Event Count in a Meta-Analysis (Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus)

Published:November 26, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.11.016
      We identified an erroneous event number in the report by Patil et al
      • Patil H.R.
      • Al Badarin F.J.
      • Al Shami H.A.
      • Bhatti S.K.
      • Lavie C.J.
      • Bell D.S.
      • O'Keefe J.H.
      Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
      entitled “Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus,” published in the (2012) 110th issue of The American Journal of Cardiology. Figures presented in the meta-analysis are not consistent with the data from the report by Chan et al
      • Chan J.C.
      • Scott R.
      • Arjona Ferreira J.C.
      • Sheng D.
      • Gonzalez E.
      • Davies M.J.
      • Stein P.P.
      • Kaufman K.D.
      • Amatruda J.M.
      • Williams-Herman D.
      Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
      entitled “Safety and Efficacy of Sitagliptin in Patients With Type 2 Diabetes and Chronic Renal Insufficiency” published in the tenth issue of Diabetes, Obesity and Metabolism (2008).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Patil H.R.
        • Al Badarin F.J.
        • Al Shami H.A.
        • Bhatti S.K.
        • Lavie C.J.
        • Bell D.S.
        • O'Keefe J.H.
        Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
        Am J Cardiol. 2012; 110: 826-833
        • Chan J.C.
        • Scott R.
        • Arjona Ferreira J.C.
        • Sheng D.
        • Gonzalez E.
        • Davies M.J.
        • Stein P.P.
        • Kaufman K.D.
        • Amatruda J.M.
        • Williams-Herman D.
        Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
        Diabetes Obes Metab. 2008; 10: 545-555

      Linked Article

      • Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
        American Journal of CardiologyVol. 110Issue 6
        • Preview
          Patients with type 2 diabetes mellitus (DM) have a very high risk for major adverse cardiovascular (CV) events. Previous studies have shown that traditional oral diabetic medications, despite lowering blood glucose levels, generally do not improve CV outcomes. The safety of some oral hypoglycemic medications has been questioned. We aimed to evaluate the CV safety of dipeptidyl peptidase-4 (DPP4) inhibitors, a novel class of oral diabetic medications, by performing a meta-analysis of DPP4 inhibitors for type 2 DM.
        • Full-Text
        • PDF
      • Reply
        American Journal of CardiologyVol. 115Issue 6
        • Preview
          We would like to thank Buisson et al1 for discovering the error in our previous meta-analysis and commend them for their diligence. We have reviewed the raw numbers of major adverse cardiovascular events (MACE) from our previous meta-analysis2 and confirmed that the MACE we recorded from the report by Chan et al3 were erroneous. In retrospect, the 2 abstracters recording this information both inadvertently used the events listed in Table 5 of the report by Chan et al, which depicted projected events per 100 patient-years of therapy (10 and 12 for sitagliptin and control groups, respectively), rather than actual events as listed in Table 4 of the report by Chan et al (11 and 1 for sitagliptin and control groups, respectively).
        • Full-Text
        • PDF